Introduction
The time of this symposium coincides with the tenth anniversary of the structural characterization of gonadotrophin-releasing hormone (GnRH) (Matsuo, Baba, Nair, Arimura & Schally, 1971 ). There were then high expectations that GnRH would not only be of help in the treatment of infertility but, with the synthesis of inhibitory analogues, could also hold the key to new methods of contraception (Guillemin, 1972) . It (Rippel & Johnson, 1976; Hsueh & Erickson, 1979a, b) , receptors have been demonstrated for GnRH on the Leydig cell and ovary, and finally there is the recent discovery of a "gonadocrinin" or GnRH-like factor in the ovary and testis (Clayton, Harwood & Catt, 1979; Sharpe & Fraser, 1980a, b;  Ying, Ling, Bohlen & Guillemin, 1981) .
It is the purpose of this paper to review the ways in which GnRH can be manipulated to produce antifertility effects and to evaluate the most promising approaches to contraception. There are 3 different ways of interfering with fertility by manipulating the GnRH stimulation of the pituitary gland: (1) GnRH can be prevented from reaching its pituitary receptors by neutralization of GnRH in the hypophysial portal blood by antibodies; (2) the GnRH receptors can be blocked by chemical antagonists of GnRH; and (3) GnRH agonists exert inhibitory effects when given chronically.
severe, its use as a contraceptive in man has not been considered but there is potential in the veterinary field for a non-surgical method of castration, particularly in meat production (Fraser, 1980a; Short, 1980; Robertson, Wilson, Rowland & Fraser, 1981 (Rivier, Rivier & Vale, 1980 (Rivier et al, 1980) . Possible direct action of antagonists on the testes remains to be established.
GnRH agonists
Over the past few years most interest has been devoted to the inhibitory effects observed after chronic treatment with high doses of GnRH or its stimulatory analogues. There is irony not only in the fact that the agonists were originally developed to treat infertility, but also because these effects first came to light many years ago, during toxicity trials for GnRH, but were ill-understood and received scant attention. Thus daily treatment of rats and dogs with high doses of GnRH or amounts as low as 50 ng GnRH agonist in rats induces low plasma concentrations of testosterone (Text- fig. 2 ), involution of the testes, seminal vesicles and prostate gland (see Labrie et al, 1980; Rechenberg, Baeder & Engelbart, 1980a; Fraser, 1981a (Sharpe, 1976) Lincoln, 1980; Sharpe & Fraser, 1980c) . Most attention has been focussed on the direct inhibitory action of GnRH agonists which was suggested by the demonstration that agonists caused a decrease in testicular LH/hCG receptors and inhibited testicular steroidogenesis in hypophysectomized rats (Hsueh & Erickson, 1979b; Arimura, Serafini, Talbot & Schally, 1979) . This concept received further support from the demonstration of receptor sites for GnRH on the Leydig cell (Sharpe & Fraser, 1980a) . The stimulation of a GnRH-like factor by the testes after administration of hCG indicated that high doses of GnRH and its agonists might mimic the action of a naturally produced intra-gonadal regulator, the normal function of which was to reduce the responsiveness of the Leydig cells (Sharpe & Fraser, 1980b; Sharpe, Fraser, Cooper & Rommerts, 1981; Sharpe, 1982 (Fraser, 1980a) .
GnRH antagonists
The first group of GnRH antagonists with amino acid substitutions at positions 2, 3 and 6 were able to inhibit ovulation in rats and hamsters but milligram doses were required (e.g. de la Cruz, Coy, Vilchez-Martinez, Arimura & Schally, 1976) . Later antagonists based on a 1,2,3,6-tetra-substituted GnRH sequence could be used at 200 pg to inhibit ovulation . The testing of the anti-ovulatory properties of these antagonists in primates has been particularly frustrating. The timing of the LH surge cannot be accurately predicted as in the laboratory rat and administration of as much as 6 doses of 50 mg antagonist (<Glu-Pro'^-Pr^D-Trp^-GnRH) at 8-h intervals before the LH surge in rhesus monkeys had only limited success in preventing ovulation (Wilks et al, 1980 (Rivier et al, 1980) is awaited with interest. It will also be important to determine whether the corpus luteum could be a target for these GnRH antagonists, and whether the powerful antagonists can exert any direct effects on the ovary.
GnRH agonists
In marked contrast with the difficulties encountered using antagonists it is now firmly established that microgram doses of GnRH agonists can inhibit a wide range of reproductive functions in women and other primates. Inhibition of ovulation by chronic treatment with agonists has undoubted potential as a new method of contraception while the induction of inadequate luteal function, premature luteolysis, and inhibition of implantation and pregnancy are also targets of these inhibitory actions (for reviews, see Corbin et al, 1978; Fraser, 1981a) .
Several years ago it was observed that high doses of GnRH or its agonists prevented implantation when administered to rats on Days 1-7 of pregnancy, and caused abortion when given on Days 7-12 (Bex & Corbin, 1978 (Clayton et al, 1979) .
One problem in using luteolytic agents for contraception is that their action may be prevented by the presence of hCG, produced after implantation. When hCG was administered with the GnRH agonist in a regimen that normally caused luteolysis, the life of the corpus luteum was prolonged (Bergquist et al, 1980b; Casper, Sheehan & Yen, 1980b (Casper et al, 1980b) . Correspondingly, the inhibitory actions of GnRH on progesterone secretion by rat luteal cells in vitro can be overcome by high concentrations of hCG (Clayton et al, 1979 (Nillius, Bergquist & Wide, 1978; Bergquist et al, 1979b; Fraser, Laird & Blakeley, 1980;  Text-fig. 4) (Fraser, , 1981b . In these studies individual variations were observed in the concentrations of oestradiol-17ß in the blood. For (Bergquist et al, 1979b; Schmidt-Gollwitzer et al, 1981 ; Text-fig. 5 ).
The pattern of oestradiol-17ß secretion during GnRH agonist administration to prevent ovulation requires careful consideration. Although the agonist itself is probably devoid of direct side-effects, the change in exposure to oestrogen in the absence of progesterone can have important consequences. Low levels of oestradiol-17ß might lead to menopausal symptoms, fig. 4) show that some follicular maturation takes place, as indicated by a rise in blood oestradiol-17ß values but the high levels ofLH induced, and the disturbance of the normal pattern of LH pulses to which the follicle is normally exposed, presumably cause a disruption in the maturation process. This can be induced in women by administering hCG during the follicular phase (Friedrich, Kemeter, Salzer & Breitenecker, 1975) and in the rat treatment with agonist results in a loss of LH and FSH receptors on the ovary (Cusan et al, 1979) .
Although the concept of direct inhibitory actions of GnRH on the ovary has generated much excitement recently, the effects were glimpsed several years ago. Rippel & Johnson (1976) found that, surprisingly, even in the hypophysectomized rat, GnRH agonist could still inhibit hCG-induced ovarian and uterine weight gain. Ying & Guillemin (1979) demonstrated that gonadotrophin-induced ovarian weight gain in hypophysectomized immature rats could be blocked by GnRH agonist in a dose-dependent manner, as little as 80 ng agonist twice daily being effective. In addition, the agonist prevented hCG-induced ovulation in these animals. Binding sites for GnRH are present on rat granulosa cells (Clayton et al, 1979; Jones, Conn, and progesterone by granulosa cells from immature hypophysectomized rats (Hsueh & Erikson, 1979a) . Furthermore, GnRH may mimic the action of ovarian gonadocrinin which may normally be involved in inducing follicular atresia (Ying et al, 1981; Sharpe, 1982) .
In addition, pituitary responsiveness is reduced after chronic treatment with GnRH agonists (Bergquist et al, 1979c; Fraser et al, 1980) and the LH surge is inhibited (Fraser et al, 1980) . Administration of oestradiol benzoate, which causes an LH surge in normal monkeys, fails to induce a surge or causes only a diminished or delayed rise in LH in stump-tailed macaques treated chronically with GnRH agonist (Fraser, 1981b; Text-fig 6) . Since the pituitary gland is normally exposed to pulses of GnRH from the hypothalamus and since this is particularly important in the primate for the action of oestrogen on the anterior pituitary gland to release LH (see Knobil, 1980, for (Clayton, Solano, Garcia-Vela, Dufau & Catt, 1980) .
We cannot yet say just how all these mechanisms work together but they present an impressive number of sites on which the agonists may exert effects that lead to contraception. 
